Ambroxol Ocular Formulations for Dry Eye Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Dry Eye Disease (DED) often fail to provide sufficient symptom relief, are tedious, and expensive, with existing approaches not adequately addressing the multifactorial nature of the disease, including tear film instability and ocular surface inflammation.
Innovation Solution
Formulations containing Ambroxol and/or its derivatives, dispersed in a carrier such as a sterile saline solution, potentially combined with biocompatible polymers for extended release, are applied topically to stimulate the conjunctiva, improve tear film homeostasis, and include additives like lubricants and preservatives, available in various forms including drops, gels, and ointments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current clinical approaches (lubricants, punctal occlusion, anti-inflammatory agents) are used to treat DED, then some symptom relief is provided, but a large portion of patients do not receive sufficient relief and treatment is tedious and expensive
Solution Approach 1:
The patent changes the pharmacological parameter by introducing ambroxol, a mucolytic agent with unique properties not previously used for ocular surface diseases. This chemical parameter change enables effective treatment of DED by stimulating tear film production and reducing inflammation, achieving sufficient symptom relief for patients who failed conventional therapies while maintaining ease of administration as simple eye drops
Solution Approach 2:
The patent employs conventional eye drop formulations that are inexpensive, easy to manufacture, and simple for patients to administer themselves. This approach makes treatment accessible and non-tedious, allowing patients to easily incorporate the therapy into their daily routines without requiring complex procedures or expensive specialized treatments
2Duration of action of stationary object
If frequent and regular use of eye drops is required for ongoing treatment, then continuous symptom relief may be maintained, but the treatment becomes tedious and demanding relative to routine daily schedules
Solution Approach 1:
The patent enables patients to self-administer simple eye drop formulations without requiring complex procedures or professional intervention. The ambroxol eye drops are designed for easy patient application, allowing individuals to independently maintain continuous symptom relief as part of their routine without significant time investment or complexity
Solution Approach 2:
By introducing ambroxol with its unique mechanism of stimulating tear film production and reducing inflammation, the patent achieves effective and sustained symptom relief that maintains continuous protection without requiring excessively frequent application, thereby reducing the time burden on patients while preserving therapeutic effectiveness
3Reliability
If conventional treatments are used for DED, then some ocular surface protection is provided, but the multifactorial nature of the disease including tear film instability and ocular surface inflammation is not adequately addressed
Solution Approach 1:
The patent employs ambroxol, a single agent that simultaneously addresses multiple pathogenic mechanisms of DED: it stimulates tear film production to address tear film instability, reduces ocular surface inflammation, and protects the ocular surface. This multi-functional approach comprehensively treats the multifactorial nature of DED through a single, simple eye drop formulation rather than requiring multiple separate therapies
Data Source
AI summary
Formulations for treating ocular surface diseases, such as dry eye disease, and related methods are disclosed. The formulations include ambroxol or a chemical derivative thereof (for example, ambroxol hydrochloride) dispersed in a carrier and may optionally include a biocompatible polymer to provide extended release properties.